Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis – Tuesday, October 14, 2025

Current Status

Not Enrolled

Price

Free

Get Started

Rajshekhar Chakraborty, Meletios-Athanasios Dimopoulos

Course Content

Course Satisfaction